Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Intrinsic Value
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and e... [ Read More ]
The intrinsic value of one
CRNX
stock under the Base Case scenario is
10.58
USD.
Compared to the current market price of 49.38 USD,
Crinetics Pharmaceuticals Inc
is
Overvalued by 79%.
CRNX's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
CRNX or that its price is influenced by factors unrelated to fundamentals.
Crinetics Pharmaceuticals Inc's market capitalization is 3.8B USD.
CRNX stock price is 49.38 USD.
CRNX stock (10.58 USD) is 79% less than its price (49.38 USD).
CRNX. Open DCF Valuation
CRNX stock (10.58 USD) is 79% less than its price (49.38 USD). Open Relative Valuation
CRNX has upside potential of 26% compared to the average analyst price target.
Open Wall St Estimates
CRNX's Revenue has dropped by 54% over the past 12 months.
CRNX's ROE (Return on Equity) has significantly increased in the last 3 years from -62% to -41%, and is approaching profitability.
CRNX's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 686% to -633%, and is approaching profitability.
CRNX has negative Operating Income for the last twelve months.
CRNX has negative Net Income for the last twelve months.
CRNX's ROE (Return on Equity) for the past 12 months is negative and is equal to -41%.
CRNX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -633%.
CRNX's Revenue is forecast to grow at a rate of 181% per year over the next 3 years.
CRNX has negative Free Cash Flow for the last twelve months.
CRNX has negative three-year average ROE (Return on Equity): -51%. The company is not efficient at transforming stockholders' equity into net income.
CRNX has negative three-year average ROIC (Return on Invested Capital): -1 551%. The company is not efficient at using invested capital to generate operating income.
CRNX's short-term assets (917m USD) exceed its short-term liabilties (52m USD).
CRNX's long-term assets (978m USD) exceed its long-term liabilties (103m USD).
CRNX's D/E (Debt to Equity) is very low and is equal to 0.
CRNX's Altman Z-Score is very high and is equal to 19.29.
Valuation Backtest
Crinetics Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
CRNX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Crinetics Pharmaceuticals Inc
Balance Sheet Decomposition
Crinetics Pharmaceuticals Inc
| Current Assets | 917.2m |
| Cash & Short-Term Investments | 901m |
| Receivables | 8.6m |
| Other Current Assets | 7.7m |
| Non-Current Assets | 60.9m |
| PP&E | 57.6m |
| Other Non-Current Assets | 3.3m |
| Current Liabilities | 51.8m |
| Accounts Payable | 10.8m |
| Accrued Liabilities | 38.5m |
| Other Current Liabilities | 2.5m |
| Non-Current Liabilities | 51.5m |
| Other Non-Current Liabilities | 51.5m |
Earnings Waterfall
Crinetics Pharmaceuticals Inc
|
Revenue
|
2m
USD
|
|
Operating Expenses
|
-250.1m
USD
|
|
Operating Income
|
-248.2m
USD
|
|
Other Expenses
|
12.7m
USD
|
|
Net Income
|
-235.5m
USD
|
Free Cash Flow Analysis
Crinetics Pharmaceuticals Inc
CRNX Profitability Score
Profitability Due Diligence
Crinetics Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Crinetics Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
CRNX Solvency Score
Solvency Due Diligence
Crinetics Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Crinetics Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRNX Price Targets Summary
Crinetics Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
CRNX
is 62.3 USD
with a low forecast of 40.4 USD and a high forecast of 101.85 USD.
Ownership
CRNX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CRNX Price
Crinetics Pharmaceuticals Inc
| Average Annual Return | 5.63% |
| Standard Deviation of Annual Returns | 67.83% |
| Max Drawdown | -58% |
| Market Capitalization | 3.8B USD |
| Shares Outstanding | 78 744 400 |
| Percentage of Shares Shorted | 6.78% |
CRNX News
Last Important Events
Crinetics Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Crinetics Pharmaceuticals Inc
Company Profile
Crinetics Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 143 full-time employees. The company went IPO on 2018-07-18. The firm is focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company has discovered a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) to treat a rare endocrine disease. Its product candidates include paltusotine, CRN04777 and CRN04894. Its paltusotine is in clinical development for the treatment of acromegaly and neuroendocrine tumors. CRN04777 is an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5), agonist designed for the treatment of congenital hyperinsulinism (HI). CRN04894 is an investigational, oral, nonpeptide product candidate designed for the treatment of diseases caused by excess adrenocorticotrophic hormone (ACTH), including Cushings disease, congenital adrenal hyperplasia (CAH), and Ectopic ACTH Syndrome (EAS).
Contact
IPO
Employees
Officers
The intrinsic value of one
CRNX
stock under the Base Case scenario is
10.58
USD.
Compared to the current market price of 49.38 USD,
Crinetics Pharmaceuticals Inc
is
Overvalued by 79%.
You don't have any saved screeners yet
